AMRS went up 10% yesterday did any of you notice?
I just did. That's why I take the time to put together these watch lists to separate the now from the good idea and to make sure we have the type of stock that can double.
I already own AMRS 2000 shares at $4.40 right where it is now.
I have test ridden this one through an earnings miss -13% that day and weak hands shake out and the sock is back to where it was. I like that action.
AMRS Fuel- 2 DIVISIONS--- DIESEL & JET!
- Down in Brazil AMRS is powering buses with their sugar cane based fuel!, in São Paulo and Rio. The Brazilian fuels regulator, ANP, recently approved the expanded use of AMRS renewable diesel to an additional 135 buses from the 180 already in place in São Paulo. AMRS will begin delivering these additional volumes in the second half of this year.POINT 1
- The Jet fuel has been tested and it works! AMRS successfully tested their renewable jet fuel in a passenger plane. AMRS is now focused on the lengthy ASTM certification process for their jet fuel. AMRS is in advanced discussions with Azul Airlines for an uptake agreement for delivery, following regulatory and certification approvals, which AMRS hope will be completed in 18 to 24 months. POINT 2
- ... Amyris will continue building its fuel business in Brazil and may later add this to the global joint venture with Total. Point 3. AMRS is holding onto the Fuel part for now.
- AMRN is in the cosmetics game:
I'm excited about " squalene " What is squalene? It is a best in class cosmetic emollient. Usually they abuse Sharks for this squalene or use petro oils... AMRS squalene has been well received by the industry and during the 2nd qtr shipments began to their US distributor (Centerchem) This now makes AMRN a global player in cosmetics supply having on the Japanese side Nikko to distribute and on the US Centerchem. The squalene market is ever widening and broadening-- it goes in hair products and in some cases on apparel. Squalene is now " coded " with three of the top cosmetic manufacturers in the world. Being coded means AMRS squalene will be among a limited set of ingredients.
Ok- What do we have so far? We have potentially cured the high price of corn, we have fixed the diesel problem; we are powering buses and planes on sugarcane; we are naturally enhancing makeup of the ladies and would you like another application?- How about the huge tire market? And the hippy dippy fragrance oil market?
AMRS also makes farnesene which can be used as a building block chemical for liquid rubber and oxygen scavengers, as well as somehow a fragrance oil. AMRS has produced a large batch test of farnesene laced fragrance oil, various perfumers are in final stages of evaluating the oil's purity and quality, and AMRS is getting ready for production on that end. Larger market than you think. Aromatherepy.
Working with Kuraray, AMRS's Japanese partner for liquid polymers, AMRS is also making considerable progress in increasing the market opportunities for liquid farnesene rubber, LFR. Major tire manufacturers have told AMRS that this is one of the most interesting monomer innovations in the last 50 years. Six of the 12 leading global tire manufacturers are currently testing liquid farnesene in their rubber formulations.... That's a golden ticket if it hits....
What's nice is this is all Green investing, high performance, cost effective, renewable products that have a positive impact in enabling sustainable growth, without subsidies....
AMRS is supported by over-60 patents, plus nearly 300 pending U.S. and foreign patent applications.
Amyris, Inc. (AMRS): Integrated renewable products company, offers renewable compounds for a variety of markets. Market cap at $255.26M, most recent closing price at $4.35. Float short at 20.51%.
***** INSIDER EDGE ALERT**** Over the last six months, insiders were net buyers of 2,288,360 shares, which represents about 10.88% of the company's 21.03M share float.
(AMRS):5-year projected EPS growth at 21.00%. Net institutional purchases in the current quarter at 1.3M shares, which represents about 6.3% of the company's float of 20.64M shares.
I suppose the danger here is in the big thinking. I've been down this investment road before, I've been in the electric battery game and the new way of making plastic bags that biodegrate into the earth (MBLX) I've been all over these save the world plays, the wave power company (OPTT) , solar (CSIQ), I could go on and on... That might give you some pause in following my lead here and it should.
I'll add I use TA a lot more now than back in the day when stocks flew around more on pure speculation. Now an private investor must get as many added benefits that he can in an investment-- Insider Activity so few companies buy anymore has become a real good tell and in this case wqe have it. Check.
Inst ownership is going down on all these tech stocks yet it is up here at AMRS. Check.
The Chart is about to break through resistance and take off today. Check. BUYING MORE AMRS! ~stoney
PS: Ethanol's Future?
(paragraph taken from old seeking alpha article on ethanol)
The sole remaining hope corn ethanol producers have for future growth is Brazil. Those familiar with the science and economics of ethanol production from sugar cane relative to corn will be surprised by this; cane is a superior ethanol feedstock to corn. While this characteristic can be attributed to several factors, the most important one is that cane sugar is fermentable in its natural state. Corn starch is not and substantial money and energy goes into depolymerizing corn starch into fermentable sugars. Other things being equal, corn ethanol is significantly more expensive to produce than cane ethanol as a result.
Hummmmmmmm.
Stoney...
I stumbled upon this old thread of yours because I was searching to see if anyone here, (predominantly you as this forum goes lol) had ever mentioned this stock.
$AMRS
$3.50
Well they are back in the news and up 5% on above average volume.
___________________
Amyris scales production of its first yeast-created cannabinoid
Move over CBD,’ is the attitude of
Amyris, Inc. (Nasdaq: AMRS) which says it’s successfully scaled the commercial production of it’s first cannabinoid, cannabigerol.
In
a statement Tuesday, the U.S.
synthetic biotech company said it expects to deliver around 1,000 kilograms of high-purity CBG via its industrial fermentation process.
Companies like
Cronos Group Inc. (TSX: CRON) and
Willow Biosciences Inc. (TSX: WLLW) have invested heavily in technology to create cannabinoids by gentically programming yeast to produce them. Such methods have the potential to produce active compounds found in the cannabis plant at a fraction of the cost of traditional cultivation.
Read more: Creating cannabinoids from yeast: why it could mean trouble for extractors
In the case of CBG, it occurs at very low concentrations in cannabis but research shows could have potent
anti-inflammatory,
anti-bacterial and
anti-cancer properties. According to
Leafly, cannabigerolic acid (CBGA) is the precursor to the three main cannabinoid lines: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA). Enzymes then “direct” CBGA to one of the other lines. Once the resulting acids are exposed to ultraviolet light or heat, they become the familiar cannabinoids THC and CBD.
“CBG is the precursor from which all other cannabinoids are synthesized and is often referred to as the ‘stem cell’ of cannabinoids,” Amyris says. “CBG is a non-psychoactive cannabinoid and presents significant therapeutic potential, making it a subject of great interest for researchers and consumers alike. Amyris’s fermentation process is well-positioned to result in the lowest cost CBG with higher purity (no THC), which is expected to unlock CBG’s adoption.”
Statista estimates the global skincare market to grow to nearly $190 billion by 2025. Photo via University of California, San Francisco
Amyris says it anticipates first commercial revenues from CBG sales this year as an ingredient in applications excluded from its collaboration agreements. The company expects product margins to be above current industry averages of publicly traded CBD suppliers.
Early testing on skin models demonstrates better performance of CBG for various topical indications over CBD, Amyris says. The company claims that combining CBG with its sugar cane-based squalene produces some of the highest efficacy results for topical applications.
Preliminary studies from the company indicate CBG has the potential to deliver better results than CBD in about one third of current CBD topical use cases.
CEO John Melo says his company is excited about the disruptive nature of this molecule for skin care, through its flavour and fragrance partnerships as well as its cosmetic distribution channels.
“This is the tenth product we deliver at scale through our fermentation platform, and reaffirms the continued expansion of our portfolio and our growth ambition to provide sustainably and economically produced natural ingredients,” he said in the statement.
Last March, Amyris signed a US$300 million cannabinoid development, licensing and
commercialization deal with U.S. cannabis extractor Lavvan Inc.
According to COO Eduardo Alvarez, Amyris’s CBG molecule was developed from initial target to full-scale production in less than nine months.
Company stock rose 4 per cent Tuesday to US$3.41 on the Nasdaq.
https://mugglehead.com/amyris-scales-production-of-its-first-yeast-created-cannabinoid/
